List of Excipients in Branded Drug ACUVAIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	HYDROCHLORIC ACID
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	SODIUM CHLORIDE
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	SODIUM HYDROXIDE
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	TRISODIUM CITRATE DIHYDRATE

ACUVAIL Excipient Strategy and Commercial Opportunities in Ketorolac Ophthalmic Formulations

Last updated: August 13, 2026

ACUVAIL is a preservative-free, single-dose ophthalmic solution containing ketorolac tromethamine 0.45%. Its commercial differentiation comes less from the active ingredient than from excipient control, dose concentration, preservative-free packaging, ocular tolerability, and reduced dosing frequency after cataract surgery. The strongest opportunities are preservative-free generic or authorized-generic products, improved unit-dose packaging, manufacturing-cost reduction, and differentiated formulations that reduce ocular surface stress.

What is ACUVAIL and how does its formulation differ?

ACUVAIL is indicated for the treatment of ocular pain and inflammation after cataract surgery. The labeled regimen is one drop in the affected eye twice daily for two days, beginning one day before surgery, on the day of surgery, and for the first postoperative day. The product is supplied in single-dose vials and does not contain an antimicrobial preservative. [1]

Product characteristic	ACUVAIL
Active ingredient	Ketorolac tromethamine
Strength	0.45% ophthalmic solution
Dosage form	Sterile topical ophthalmic solution
Administration	One drop twice daily
Primary use	Postoperative ocular pain and inflammation
Container	Single-dose vial
Preservative	None
NDA	202880
Approval period	2010
Key differentiation	Lower dosing frequency and preservative-free unit-dose delivery

ACUVAIL is distinct from conventional ketorolac tromethamine ophthalmic products commonly marketed at 0.5%. The 0.45% concentration does not by itself establish product differentiation. The commercial value lies in the combination of concentration, formulation performance, dosing schedule, packaging, and clinical or regulatory support.

What excipients are used in ACUVAIL?

The FDA prescribing information identifies sodium chloride, sodium citrate dihydrate, citric acid, sodium hydroxide and/or hydrochloric acid for pH adjustment, and purified water as inactive ingredients. [1]

Excipient	Functional role
Sodium chloride	Tonicity adjustment
Sodium citrate dihydrate	Buffering and pH control
Citric acid	Buffer system and pH adjustment
Sodium hydroxide and/or hydrochloric acid	Final pH adjustment
Purified water	Aqueous vehicle

The formulation uses a relatively conventional aqueous excipient system. Its commercial challenge is not excipient novelty in isolation. The challenge is achieving all of the following simultaneously:

• Chemical stability of ketorolac tromethamine.
• Sterility throughout manufacturing and filling.
• Acceptable osmolality and ocular tolerability.
• Reliable pH control.
• Low particulate burden.
• Consistent drop delivery from a unit-dose container.
• Adequate shelf life without preservatives.
• Compatibility with container-closure materials.

How does the ACUVAIL excipient strategy create commercial value?

The excipient strategy supports four product attributes with direct commercial relevance.

Preservative-free dosing

Preservative-free delivery is important for postoperative patients who may receive several topical products. Benzalkonium chloride and other preservatives can contribute to ocular-surface irritation, epithelial toxicity, or cumulative exposure when multiple ophthalmic drugs are used. A preservative-free formulation can support hospital, ambulatory surgery center, and ophthalmologist preference.

The tradeoff is higher packaging and manufacturing cost. A multidose preserved bottle is generally less expensive per labeled dose than individually filled unit-dose containers. A competing product must therefore offset the cost disadvantage through simpler sterile processing, improved fill efficiency, lower material cost, or stronger formulary positioning.

Lower administration frequency

ACUVAIL is dosed twice daily, while conventional ketorolac 0.5% ophthalmic products have historically used more frequent administration. Lower frequency can reduce patient and caregiver burden and improve adherence during the immediate postoperative period.

The formulation strategy must establish that the lower concentration and lower dosing frequency deliver adequate exposure at the ocular surface. This creates a potential regulatory barrier for a copy product that cannot rely solely on the concentration of the active ingredient.

Unit-dose packaging

Single-dose packaging eliminates the need for a preservative and reduces the risk of contamination after opening. It also permits a defined amount of drug to be allocated for the short postoperative treatment period.

The package is part of the product strategy, not merely a manufacturing component. Opportunities include lower-cost blow-fill-seal containers, improved vial ergonomics, tamper-evident packaging, and package counts aligned with the two-day regimen.

Buffer and tonicity control

The citrate buffer and sodium chloride system must maintain product quality without creating unacceptable ocular discomfort. Excipient levels affect pH, osmolality, drug solubility, hydrolysis, and drop comfort.

A generic developer should optimize the complete formulation rather than substitute excipients solely to reduce cost. A different buffer system may introduce new extractables, stability, toxicology, or bioequivalence issues.

What formulation patents protect ACUVAIL?

ACUVAIL protection must be assessed through the FDA Orange Book, United States Patent and Trademark Office records, and litigation databases. The FDA label identifies the NDA and formulation but does not, by itself, provide a complete patent-rights analysis. [1,2]

The relevant protection categories are:

Protection category	Relevance to ACUVAIL
Active-ingredient patents	Limited practical relevance because ketorolac is an established drug
Composition patents	May cover concentration, excipient ratios, pH, osmolality, or stability
Method-of-use patents	May cover postoperative pain or inflammation treatment and dosing schedules
Packaging patents	May cover unit-dose delivery or container-closure systems
Manufacturing patents	May cover sterile filling, filtration, or preservative-free production
Regulatory exclusivity	Historically relevant after 2010 approval; any original period has expired

ACUVAIL was approved in 2010. The standard three-year Hatch-Waxman exclusivity associated with a new clinical investigation would have expired no later than 2013 if granted for the relevant application. Five-year new chemical entity exclusivity would not generally apply because ketorolac was previously approved. [3,4]

Patent expiration depends on the specific listed patent, patent-term adjustment, patent-term extension, terminal disclaimers, and any litigation settlement. A developer should not treat the original approval date as a substitute for a patent-clearance analysis.

When does ACUVAIL lose exclusivity?

ACUVAIL’s regulatory exclusivity has expired. Commercial entry depends primarily on remaining patent claims, FDA approval requirements, product availability, and manufacturing economics.

For an ANDA applicant, the principal routes are:

1. Paragraph III certification, accepting a listed patent’s expiration.
2. Paragraph IV certification, asserting that a listed patent is invalid, unenforceable, or not infringed.
3. A section viii statement, where the applicant seeks approval without the patented method of use.
4. A 505(b)(2) application for a differentiated formulation, delivery system, or use.

A conventional generic product that copies the formulation and indication would face the greatest risk from composition and method-of-use patents. A product with a different excipient system may reduce composition-claim exposure but can increase formulation-development and bioequivalence risk.

What generic entry risks exist for ACUVAIL?

The principal generic-entry risks are formulation equivalence, unit-dose manufacturing, and market size.

Formulation and bioequivalence risk

Topical ophthalmic products are subject to complex equivalence considerations. A developer must address active concentration, pH, osmolality, viscosity, surface tension, droplet size, particle size where applicable, preservative status, and container-closure performance. FDA guidance recognizes that ophthalmic products may require a combination of pharmaceutical equivalence, product-quality comparison, and clinical or in vitro evidence. [5]

A generic at 0.45% is more commercially relevant than a generic at 0.5% because it would compete directly with ACUVAIL’s labeled concentration and dosing profile. A 0.5% product may compete clinically but would not necessarily be substitutable at the pharmacy level.

Manufacturing risk

Preservative-free ophthalmic production requires validated aseptic processing or an appropriate sterile manufacturing process. Unit-dose filling increases line complexity and packaging consumption. Critical controls include:

• Sterilizing filtration or validated terminal sterilization, where compatible.
• Aseptic filling accuracy.
• Container-closure integrity.
• Low visible and subvisible particulate levels.
• Extractables and leachables control.
• Drop-volume consistency.
• In-use handling instructions.

The manufacturing barrier is meaningful but not insurmountable for established ophthalmic manufacturers.

Commercial risk

The cataract-surgery market is large, but ketorolac is exposed to price competition from older ophthalmic NSAIDs, combination postoperative regimens, and lower-cost 0.5% products. A generic ACUVAIL product must compete against both branded differentiation and established generic prescribing behavior.

Potential customers include:

• Retail pharmacies.
• Ophthalmology practices.
• Ambulatory surgery centers.
• Integrated delivery networks.
• Pharmacy benefit managers.
• Institutional surgical formularies.

What commercial opportunities exist in ACUVAIL excipients?

Opportunity 1: Lower-cost preservative-free generic

The clearest opportunity is a 0.45% preservative-free generic using a comparable aqueous buffer system and lower-cost unit-dose packaging. Manufacturing scale, vial resin selection, automated filling, and optimized carton counts can improve gross margin.

The product must preserve the attributes that drive ACUVAIL selection: preservative-free status, twice-daily dosing, reliable drop delivery, and short-course packaging.

Opportunity 2: Improved unit-dose container

A container that is easier to open, less prone to tip deformation, and more consistent in drop formation could differentiate a generic without changing the active formulation. Packaging improvements may also reduce product loss and improve administration by elderly postoperative patients.

Potential intellectual-property claims could cover container geometry, dispensing apertures, closure design, or package configuration.

Opportunity 3: Ocular-surface comfort

A reformulated product could target lower sting, reduced epithelial stress, or improved tolerability through controlled osmolality, optimized buffering, or alternative excipients. This opportunity has commercial value but carries greater regulatory risk.

Changes to buffer composition or ionic strength may affect drug stability and ocular exposure. A 505(b)(2) pathway could be relevant for a materially differentiated product, but the cost and evidence burden would be higher than for an ANDA.

Opportunity 4: Combination postoperative therapy

A combination product containing an NSAID and another postoperative agent could reduce the number of bottles used after cataract surgery. Possible combinations may involve an antibiotic, corticosteroid, or other anti-inflammatory agent.

This strategy faces substantial development barriers, including compatibility, preservative status, stability, dosing alignment, clinical evidence, and potentially separate patent estates for each active ingredient.

Opportunity 5: International formulation licensing

Outside the United States, opportunities may exist through licensing of:

• Preservative-free ophthalmic manufacturing technology.
• Blow-fill-seal unit-dose capacity.
• Regional sterile ophthalmic distribution.
• Formulation know-how for ketorolac or related NSAIDs.
• Hospital and surgery-center supply contracts.

Geographic freedom to operate must be analyzed separately because patent expiry, product registration, reference-product requirements, and packaging standards differ by jurisdiction.

How does ACUVAIL compare with conventional ketorolac ophthalmic products?

Attribute	ACUVAIL	Conventional ketorolac ophthalmic product
Typical strength	0.45%	Often 0.5%
Preservative	None	May contain a preservative
Packaging	Single-dose vial	Often multidose bottle
Dosing burden	Lower labeled frequency	Often more frequent
Cost structure	Higher packaging cost	Lower packaging cost
Differentiation	Preservative-free and low-frequency regimen	Established generic availability
Generic substitution	Depends on approved strength and formulation	Broad generic competition

ACUVAIL’s commercial advantage is strongest where surgeons or institutions value preservative-free postoperative treatment and simplified dosing. Its disadvantage is the cost of unit-dose sterile packaging and the availability of lower-priced ketorolac alternatives.

What is the FDA regulatory status of ACUVAIL?

ACUVAIL was approved under an NDA as a sterile ophthalmic solution. It is not a biologic, so biosimilar pathways do not apply. The relevant competitive pathway is an ANDA for a therapeutically equivalent generic or a 505(b)(2) application for a materially differentiated formulation. [1,3,5]

FDA regulatory priorities for a competing product include:

• Pharmaceutical equivalence.
• Sterility assurance.
• Container-closure integrity.
• Stability.
• Extractables and leachables.
• Drop size and delivery performance.
• Preservative-free labeling.
• Appropriate postoperative indication and dosing.

Which companies are positioned to challenge ACUVAIL?

The most credible challengers are established ophthalmic manufacturers with sterile filling capability, including generic pharmaceutical companies and contract manufacturers with ophthalmic platforms. The commercial advantage will favor companies that already supply cataract-surgery products and can bundle ketorolac with corticosteroid or antibiotic products.

Potential challenger profiles include:

• Large generic manufacturers with ANDA infrastructure.
• Ophthalmology-focused companies with established prescriber relationships.
• Contract development and manufacturing organizations with aseptic unit-dose capacity.
• Specialty pharmaceutical companies pursuing preservative-free ophthalmic products.
• Regional manufacturers seeking hospital and ambulatory surgery contracts.

No biosimilar competition is relevant. The primary threat is generic or reformulated small-molecule competition.

What patent litigation and settlement issues affect ACUVAIL?

Paragraph IV risk depends on the current Orange Book listing and the claims asserted against a particular ANDA. The key litigation questions are whether a listed patent covers:

• The 0.45% ketorolac concentration.
• The specific buffer and tonicity system.
• Preservative-free packaging.
• The twice-daily postoperative regimen.
• A manufacturing process.
• A container-closure configuration.

A settlement could establish an agreed generic-entry date, a license, a manufacturing arrangement, or restrictions on product launch. Such terms can materially affect valuation even when a patent appears vulnerable.

No commercial diligence should assume that the absence of a readily visible composition patent eliminates litigation risk. Method-of-use claims and packaging claims may remain relevant, and patent status can differ between the United States, Europe, Canada, Japan, and other markets.

How strong is the ACUVAIL patent estate?

The likely strength of the estate is mixed.

Patent category	Relative strength
Ketorolac active ingredient	Low, because the molecule is old
Broad ophthalmic solution claims	Low to moderate
Narrow 0.45% composition claims	Moderate if supported by unexpected results
Preservative-free formulation claims	Moderate, depending on claim scope
Dosing-regimen claims	Moderate but vulnerable to validity and infringement defenses
Packaging claims	Variable
Manufacturing claims	Potentially stronger if process-specific and difficult to design around

The most defensible claims would typically be narrow claims tied to a defined concentration, excipient range, stability profile, delivery system, or unexpected clinical benefit. Broad claims covering ketorolac ophthalmic solutions are more exposed to prior-art challenges.

What revenue exposure and launch scenarios exist?

The product’s revenue exposure depends on branded sales, institutional contracting, generic price erosion, and the extent to which prescribers select 0.45% preservative-free therapy rather than 0.5% alternatives.

Launch scenario	Likely market effect
First therapeutically equivalent generic	Rapid price pressure and pharmacy substitution
Authorized generic	Lower external competition but reduced branded net sales
0.5% generic only	Clinical competition without direct strength substitution
Preservative-free 0.45% generic	Highest direct threat to ACUVAIL
Differentiated 505(b)(2) product	Slower launch but potentially higher pricing
Combination postoperative product	Broader regimen substitution and contracting leverage

A first generic entrant could capture substantial volume but would face rapid price erosion if multiple manufacturers enter. A differentiated preservative-free product may sustain better pricing if it obtains formulary preference or demonstrates measurable adherence and tolerability benefits.

Key Takeaways

• ACUVAIL contains ketorolac tromethamine 0.45% in a preservative-free, single-dose ophthalmic solution.
• Its excipient system uses sodium chloride, citrate buffering, pH adjusters, and purified water.
• The commercial differentiation comes from preservative-free packaging, twice-daily dosing, and postoperative positioning.
• Regulatory exclusivity from the 2010 approval period has expired.
• Generic risk depends on current Orange Book patents, formulation equivalence, method-of-use claims, and sterile unit-dose manufacturing.
• The strongest commercial opportunity is a lower-cost 0.45% preservative-free generic with reliable unit-dose packaging.
• Biosimilar competition is not relevant because ACUVAIL is a small-molecule ophthalmic drug.
• Reformulation opportunities exist in ocular comfort, packaging, and combination postoperative therapy, but these carry higher development and regulatory costs.

FAQs About ACUVAIL Excipient and Commercial Strategy

Can ACUVAIL be reformulated with benzalkonium chloride?

Yes, but doing so would remove the preservative-free differentiation and could change tolerability, labeling, packaging, and regulatory requirements. A preserved multidose product would compete primarily on cost and convenience.

Is a 0.5% ketorolac ophthalmic product substitutable for ACUVAIL?

Not automatically. ACUVAIL is labeled at 0.45%, and pharmacy substitution depends on FDA therapeutic-equivalence determinations and the approved product labeling.

Can a generic ACUVAIL use different excipients?

Potentially. The applicant must demonstrate that the formulation meets applicable pharmaceutical equivalence, quality, stability, sterility, and bioequivalence requirements. Different excipients can increase development risk.

Does ACUVAIL have biosimilar competition?

No. ACUVAIL contains ketorolac tromethamine, a small-molecule active ingredient. Generic-drug pathways, not biosimilar pathways, govern competitive entry.

What is the highest-value intellectual-property strategy for a new ACUVAIL competitor?

A narrow, technically supported strategy covering preservative-free composition parameters, unit-dose delivery, improved stability, or clinically relevant tolerability is more defensible than a broad claim to ketorolac ophthalmic use.

References

1. U.S. Food and Drug Administration. (2024). ACUVAIL (ketorolac tromethamine ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format of an abbreviated new drug application.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (2023). Draft guidance for industry: Ophthalmic drug products administered by topical routes: Bioavailability and bioequivalence studies.